Two patients presented with hypophosphataemic osteomalacia and were subsequently found to have small tumours of unusual histopathology and location causing the osteomalacia. Each tumour was found after an intensive search for occult masses. Studies of vitamin D metabolism and renal tubular function before and after surgery yielded further insight into the pathophysiology of oncogenic osteomalacia. These cases demonstrate that microscopic quantities of tumour are capable of causing the syndrome and further illustrate the high index of suspicion often necessary to locate causative tumours in patients with hypophosphataemic osteomalacia.
Introduction
In 1947, McCance described a patient with dramatic resolution of chronic hypophosphataemia and severe osteomalacia after resection of a soft tissue tumour. Since then, at least 32 additional reports have described a similar clinical entity completely cured by tumour removal, a syndrome now referred to as oncogenic osteomalacia (Agus, 1983a; Fukumoto et al., 1979; Weidner et al., in press ). Patients with oncogenic osteomalacia characteristically present with a low renal threshold for phosphate reabsorption (TmPO4/GFR) (Walton & Bijvoet, 1975) , hypophosphataemia, and osteomalacia. We now report two cases of oncogenic osteomalacia which detail the bizarre location, behaviour, and pathology of the tumours that can be associated with this disorder.
Case reports
Case I This white male was first seen in June 1978 at age 34 with a 1 year history of back stiffness and lower extremity weakness. On physical examination there was a wide-based shuffling gait. Plain films of the pelvis showed diffuse osteopenia. Serum phosphate was 0.52mmol/1 (normal 0.81-1.45mmol/1). There was no history of diarrhoea, alcohol abuse, antacid or diuretic use. By August 1978 his symptoms had progressed and he was forced to stop work as a postman. Physical examination then showed difficulty arising from a squatting position with decreased strength in his hip flexors and abductors. His gait was waddling with an abductor lurch to the left. A small 2 x 3cm firm non-tender immobile nodule on the mid-palmar surface of the left hand was noted ( Figure  1 ), the patient believing this lesion had been present for at least 5 years. Laboratory evaluation at this time showed serum phosphate averaging 0.61 mmol/l (range 0.52-0.71) with a consistently normal serum calcium (2.35 mmol/l). Alkaline phosphatase was 329 IU/l (normal < 115) with a normal gamma glutamyl transpeptidase and aspartate amino-transferase. Arterial blood pH was 7.42, urine pH 6, serum bicarbonate 26 mmol/l, and urine pH 4.9 after oral ammonium chloride loading. Twenty-four hour urines for amino acids and heavy metals were normal. No glycosuria was present and creatinine clearance was 123 ml/min. Evaluation of 24 h urine collection showed uric acid 4.2 mmol, phosphate 24.5 mmol, and Calcium 3.9 mmol. Serum carotene, prothrombin time and 72 h fecal fat were normal. Immunoreactive parathyroid hormone level (intact) (UpJohn Labs, Kalamazoo, Michigan) was normal at 226 pgeq/ml (normal 163-347 Labs, Rochester, Minnesota). Twenty-five hydroxy vitamin D3 level was normal on two different determinations and serum 1,25(OH)2D3 was low at 10 pg/ ml (normal 20-76, BioScience Labs, Van Nuys, California). Alkaline phosphatase was elevated at 132 IU/l (normal <1I15) and 24 h urinary hydroxyproline was 446 Lmol (normal < 190). Urinalysis and serum electrolytes were normal. Creatinine clearance was 107ml/min. There was no glycosuria and urine for heavy metals was negative. She was begun on oral phosphate (64mmol of elemental phosphorus/day) with no improvement in her serum phosphate or her symptoms. In January 1982 a rib biopsy obtained after tetracycline labelling demonstrated markedly widened osteoid seams characteristic of osteomalacia. A computerized tomographic (CT) scan of the lumbosacral spine showed a bone density of 90 mg of dipotassium hydrogen phosphate (greater than 2 s.d. below that for age-matched controls). Despite the addition of vitamin D, initially as ergocalciferol 25 000 units a day, then as calcitriol 0.75 ytg/d, her symptoms worsened and her serum phosphate remained low. She was not seen again until May 1983 by which time she was confined to a wheelchair because of progressive lower extremity weakness and pain. On repeat CT scan ofthe spine there was a slight decrement in bone density to 85 mg of dipotassium hydrogen phosphate.
In August 1983 she was hospitalized with the goal of optimizing her calcitriol and phosphate therapy and searching for an occult tumour possibly causing the osteomalacia. Prothrombin time, serum vitamin B12, serum carotene, 5 h xylose absorption, and 72 h fecal fat were all normal. Twenty-four hour urine for amino acids was normal. Chest X-ray and plain films of the upper and lower extremities showed only diffuse osteopenia. CT scans of the brain, chest, abdomen, and pelvis were normal. Plain films of the paranasal sinuses showed an abnormality in the right maxillary sinus interpreted by both radiology and otolaryngology consultants as a benign mucous retention cyst (Figure 3) . Calcitriol, 3.5 Ag/d, and oral phosphate had produced no serum phosphate higher than 0.77 mmol/l and no change in symptoms. Because of the failure to respond to medical therapy, surgical (Walton & Bijvoet, 1975) sive weakness were present from one to as many as 13 years (Linovitz et al., 1976 ) before the tumour is found. There is sustained hypophosphataemia with a low renal phosphate threshold and therefore marked renal phosphate wasting. There may be associated aminoaciduria (Fukumoto et al., 1979; Evans & Azzopardi, 1972; Drezner & Feinglos, 1977) or mild glycosuria. Other findings associated with proximal tubular dysfunction such as hyperuricosuria or impaired urinary acidification have not been found. Serum levels ofparathyroid hormone, calcium and 25-OH vitamin D are normal whereas the 1,25-(OH)2D3 level is uniformly low (Agus, 1983a; Drezner et al., 1982; Drezner and Feinglos, 1977; Fukumoto et al., 1979; Lau et al., 1979; Sweet et al., 1980) . Complete resolution of the clinical and metabolic abnormalities occurs upon removal of the tumour.
Two main obstacles to cure exist. First, this condition must be suspected in the patient presenting with hypophosphataemia and inappropriate phosphaturia. Second, the suspicion must be high enough to encourage a vigorous search for the offending neoplasm. Our two cases of oncogenic osteomalacia illustrate important clinical aspects of these tumours. First they can be small in size. Indeed, this meant a microscopic focus in Case 2 at the time of repeat surgery. Furthermore, they can occur in unusual locations and can be confused with common benign lesions. Therefore, there are significant potential problems in not only identifying these tumours, but often in recommending surgical intervention.
Among the features of our 2 cases that have been rarely described in previous cases of oncogenic osteomalacia is the elevated level of 24,25(OH)2D3 in Case 1. This vitamin D metabolite was normal in the single instance that it was reported in the literature (Sweet et al., 1980) . Another feature in Case 1 is the striking tumour uptake of radiotracer on bone scan. Although this has never before been reported, this imaging technique may be of value in localization of the causative tumour.
A variety of tumours have been associated with oncogenic osteomalacia. Among the most common are ossifying mesenchymal tumour, osteoblastoma, hemangiopericytoma-like tumour and nonossifying fibroma. Despite the apparent wide range of tumour type, analysis of the literature shows that approximately 80% were reported to have prominent vascularity and osteoclast-like multinucleated giant cells (Weidner et al., in press ). Light microscopic study in our cases showed intimate spatial relationship between these two components. In the cases described here, the osteoclast-like cells were rich in endoplasmic reticulum whereas other cells, at least in Case 2, had few cytoplasmic organelles, suggesting that these cells were not actively involved in significant protein synthesis. The fact that all biochemical defects rapidly reversed with complete tumour removal points toward the secretion of one or more causative substances secreted by the tumour tissue. That such substances are likely to be quite potent is evidenced by the hypophosphatemia in Case 2 caused by a microscopic residuum of tumour. Indeed, saline extracts from tumour of three different patients with oncogenic osteomalacia (Lau et al., 1979; Aschinberg et al., 1977; Popovtzer, 1981) have caused a decrease in tubular reabsorption of phosphate when injected into experimental animals.
The dramatic postoperative course of serum phosphate and 1,25(OH)2D3 seen in Case 2 (Figure 3 ) has been described only once before in the literature (Sweet et al., 1980) . We have shown, in addition, that although serum phosphate may fall shortly after surgery, the TmPO4/GFR and 1,25(OH)2D3 level begin a steady rise 24 h after tumour removal, preceding the rise in serum phosphate. This finding strongly supports the existence ofa circulating substance which depresses renal phosphate reabsorption threshold and in turn lowers serum phosphate. Any unifying explanation of the pathophysiology of the phosphaturia, however, must also account for the aminoaciduria and glycosuria seen in some patients and the low serum levels of 1,25-(OH)2D3. An agent which alters proximal nephron function to a varying extent could group.bmj.com on October 29, 2017 -Published by http://pmj.bmj.com/ Downloaded from explain all of these findings. The proximal nephron is not only the site of reabsorption of glucose and amino acids, but is also the locus for most phosphate reabsorption (Agus, 1983b) and all 25-OH D3-la hydroxylase activity (Kawashima et al., 1981) . The more pronounced hypophosphataemia and hypokalaemic hyperchloraemic metabolic acidosis that occurred shortly after the second surgery in Case 2 may have reflected a further impairment of proximal tubular function. It is interesting to postulate that an increased release of a substance(s) from the tumour tissue disrupted during surgical manipulation augmented proximal tubular dysfunction, perhaps producing a transient proximal renal tubular acidosis.
A renal phosphate leak alone cannot explain the biochemical abnormalities in oncogenic osteomalacia, especially in view of the stimulation of renal-lo-hydroxylase activity expected with phosphate depletion (Baxter & DeLuca, 1976; Rader et al., 1979) . Conversely, there is little convincing evidence showing direct effects of 1,25-(OH)2D3 on renal phosphate handling in humans (Bordier et al., 1978; Levine et al., 1978) . Although Drezner et al. (1977) showed normalization of all biochemical abnormalities after high dose 125-(OH)2D3 (3.0 pig/d), we saw no significant improvement in serum phosphate in Case 2 despite treatment with 3.5 fig of calcitriol and oral phosphate supplements. Agus (1983a) and Fukumoto et al. (1979) also observed inadequate responses after high doses of lx-(OH)D3.
The poor response to medical therapy that is often observed in oncogenic osteomalacia emphasizes the need for greater awareness of this syndrome coupled with a vigorous search for causative tumour. Further study of these patients and their neoplasms should clarify the nature of the humoral substance presumed responsible. Identification and purification of this material is likely to not only further our understanding of renal tubular function but also enable selective modulation of proximal nephron function.
